Chimeric antigen receptor CAR-T cell therapies targeting CD19 have greatly improved the prognosis for patients with relapsed/refractory large B-cell lymphoma (r/r DLBCL) [1,2,3,4,5,6]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.